30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Three-Month Interim Safety Data from Phase I Clinical Trial of AlloJoin -

Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine's AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17. (Cellular Biomedicine, 12/9/16)